nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

16.06.2016 | Original Article

Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in ¹⁸fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer

verfasst von: Shang-Wen Chen, Ying-Chun Lin, Rui-Yun Chen, Te-Chun Hsieh, Kuo-Yang Yen, Ji-An Liang, Shih-Neng Yang, Yao-Ching Wang, Ya-Huey Chen, Nan-Haw Chow, Chia-Hung Kao

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

This study examined genomic factors associated with a reduction in ¹⁸fluoro-2-deoxy-D-glucose (FDG) uptake during positron emission tomography–computed tomography (PET-CT) for definitive chemoradiotherapy (CRT) in patients with pharyngeal cancer.

Methods

The pretreatment and interim PET-CT images of 25 patients with advanced pharyngeal cancers receiving definitive CRT were prospectively evaluated. The maximum standardized uptake value (SUV_max) of the interim PET-CT and the reduction ratio of the SUV_max (SRR) between the two images were measured. Genomic data from pretreatment incisional biopsy specimens (SLC2A1, CAIX, VEGF, HIF1A, BCL2, Claudin-4, YAP1, MET, MKI67, and EGFR) were analyzed using tissue microarrays. Differences in FDG uptake and SRRs between tumors with low and high gene expression were examined using the Mann–Whitney test. Cox regression analysis was performed to examine the effects of variables on local control.

Results

The SRR of the primary tumors (SRR-P) was 0.59 ± 0.31, whereas the SRR of metastatic lymph nodes (SRR-N) was 0.54 ± 0.32. Overexpression of HIF1A was associated with a high iSUV_max of the primary tumor (P < 0.001) and neck lymph node (P = 0.04) and a low SRR-P (P = 0.02). Multivariate analysis revealed that patients who had tumors with low SRR-P or high HIF1A expression levels showed inferior local control.

Conclusion

In patients with pharyngeal cancer requiring CRT, HIF1A overexpression was positively associated with high interim SUV_max or a slow reduction in FDG uptake. Prospective trials are needed to determine whether the local control rate can be stratified using the HIF1A level as a biomarker and SRR-P.

Nur mit Berechtigung zugänglich

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed

Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.CrossRefPubMed

Ernster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117:2115–28.CrossRefPubMed

Aukema TS, Kappers I, Olmos RA, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010;51:1344–8.CrossRefPubMed

Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43.CrossRefPubMed

Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56–68.PubMed

Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck. 1994;16:340–6.CrossRefPubMed

Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–35.CrossRefPubMed

Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2011;38:1203–11.CrossRefPubMed

10.

Chen SW, Hsieh TC, Yen KY, et al. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer. Laryngoscope. 2014;124:2732–8.CrossRefPubMed

11.

Goodman MD, Tarnoff M, Kain M, Slotman GJ. Interactions between outcomes and tumour response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer. Southern New Jersey Head and Neck Cancer Treatment Group. Am J Surg. 1997;174:527–31.CrossRefPubMed

12.

Wanebo H, Chougule P, Ready N, et al. Surgical resection is necessary to maximize tumour control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol. 2001;8:644–50.CrossRefPubMed

13.

Klimowicz AC, Bose P, Petrillo SK, Magliocco AM, Dort JC, Brockton NT. The prognostic impact of a combined carbonic anhydrase IX and Ki-67 signature in oral squamous cell carcinoma. Br J Cancer. 2013;109:1859–86.CrossRefPubMedPubMedCentral

14.

Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol. 2003;179:801–11.CrossRefPubMed

15.

Akervall J, Nandalur S, Zhang J, et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 2014;50:570–81.CrossRefPubMed

16.

Couture C, Raybaud-Diogène H, Têtu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713–22.CrossRefPubMed

17.

Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128–37.CrossRefPubMedPubMedCentral

18.

McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res;46:4244s-4248s.

19.

Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.CrossRefPubMedPubMedCentral

20.

Lin SC, Liao CY, Kao CH, et al. Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer. J Radiat Res. 2012;53:462–8.CrossRefPubMed

21.

Smith TA, Zanda M, Fleming IN. Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase. Nucl Med Biol. 2013;40:858–64.CrossRefPubMed

22.

Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102:789–95.CrossRefPubMedPubMedCentral

23.

Fleming N, Manavaki R, Blower PJ, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238–50.CrossRefPubMed

24.

Brown JM, William WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.CrossRefPubMed

25.

Rajendran JG, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by 18 F-fluoromisonidazole and 18 F-fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–52.CrossRefPubMed

26.

Dierckx RA, Van De Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging. 2008;35:1544–9.CrossRefPubMedPubMedCentral

27.

Oswald J, Treite F, Haase C, et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett. 2007;254:102–10.CrossRefPubMed

28.

Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol. 1996;23:941–6.CrossRefPubMed

29.

Stubbs M, Griffiths JR. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul. 2010;50:44–55.CrossRefPubMed

30.

Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with 18F-FDG uptake in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2000;27:1778–85.CrossRef

31.

Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22–9.PubMed

Titel: Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer
verfasst von: Shang-Wen Chen
Ying-Chun Lin
Rui-Yun Chen
Te-Chun Hsieh
Kuo-Yang Yen
Ji-An Liang
Shih-Neng Yang
Yao-Ching Wang
Ya-Huey Chen
Nan-Haw Chow
Chia-Hung Kao
Publikationsdatum: 16.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3436-z

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2016

Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes

Introduction of nuclear medicine research in Japan

18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer

Crossing technological frontiers in radioguided intervention

Same-day 90Y radioembolization: implementing a new treatment paradigm

SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease